secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2022-05-03T23:59:59+00:00
Accession:  0000078003-22-000068
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer Q1 revenues $25.7B (+82%), EPS $1.62 adj.; reaffirms FY revenue $98-102B, adj. EPS $6.25-$6.45
--------------------------------------------------------------------------------

- Revenues $25.7B up 82% operationally; ex-COVID products +2% operational growth.
- Reported diluted EPS $1.37; Adjusted diluted EPS $1.62 (includes $0.05 negative from acquired IPR&D accounting change).
- Full-year revenue guidance reaffirmed $98-$102B; adjusted EPS guidance revised to $6.25-$6.45 from $6.35-$6.55.
- Comirnaty revenue guidance ~$32B; Paxlovid ~$22B; Chantix shipments remain paused globally due to impurity issue.
- Pfizer repurchased 39.1M shares for $2B in March at avg $51.10; remaining authorization $3.3B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800322000068/0000078003-22-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800322000068/pfe-20220503.htm
  HTML page:      https://secwatch.observer/filing/0000078003-22-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer